Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3973 - Baseline characteristics and first-line (1L) treatment of patients with HER2+ metastatic breast cancer (MBC) from the SystHERs registry


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Breast Cancer


Peter Kaufman


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


P.A. Kaufman1, S.A. Hurvitz2, J. O'Shaughnessy3, G. Mason4, D.A. Yardley5, A. Brufsky6, H.S. Rugo7, M. Cobleigh8, S.M. Swain9, D. Tripathy10, L. Chu11, V. Antao11, B. Yoo12, M. Jahanzeb13

Author affiliations

  • 1 Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, 3756 - Lebanon/US
  • 2 Jonsson Comprehensive Cancer Center And Translational Research In Oncology, University of California Los Angeles, Los Angeles/US
  • 3 Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology, Dallas/US
  • 4 Board Of Directors, Inflammatory Breast Cancer Research Foundation, West Lafayette/US
  • 5 Breast Cancer Research Program, Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville/US
  • 6 Cancer Institute, University of Pittsburgh, Pittsburgh/US
  • 7 Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco/US
  • 8 Department Of Internal Medicine, Rush University Medical Center, Chicago/US
  • 9 Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington/US
  • 10 Md Anderson Cancer Center, University of Texas, Houston/US
  • 11 Biooncology, Genentech, Inc., South San Francisco/US
  • 12 Biostatistics, Genentech, Inc., South San Francisco/US
  • 13 Sylvester Comprehensive Cancer Center, University of Miami, Deerfield Beach/US


Abstract 3973


The addition of pertuzumab (P) to trastuzumab (H) and docetaxel improves survival in clinical trials of patients with HER2+ MBC, and is a guideline-recommended standard of care for this population. In the real world, however, various factors may influence treatment decisions. Systematic Therapies for HER2-positive Metastatic Breast Cancer Study (SystHERs) is a fully enrolled (June 2012–June 2016), ongoing, US-based, observational study that captures real-world data for patients with HER2+ MBC. Here, we describe the baseline characteristics and treatment patterns of patients who received 1L PH or H without P.


Eligible patients had HER2+ MBC diagnosed within 6 months of enrollment and were ≥18 years of age. Patients were compared descriptively by 1L treatment (PH vs H without P), defined as any therapy received up to first progression.


As of February 10, 2017, among 978 eligible patients, 949 had received 1L treatment (PH, n = 711; H without P, n = 174; no H, n = 64) (Table). 476 (67%) and 88 (51%) of patients in the 1L PH and H without P cohorts, respectively, remain on study. Median follow-up from 1L treatment start was 22 and 25 months, respectively. In patients treated with PH, median duration of treatment with H and P were 15 and 13 months, respectively. In the H without P cohort, median duration of H was 15 months. Among all patients, 68% (648/949) received 1L PH + taxane.Table:


PH (n = 711)H without P (n = 174)
Baseline characteristics
Median age at MBC diagnosis, years (range)55 (21–89)61 (28–90)
White, n (%)565 (79)137 (79)
Eastern Cooperative Oncology Group performance score 0–1, n (%)613 (86)146 (84)
Private insurance, n (%)367 (52)83 (48)
Urban or suburban living location, n (%)556 (78)138 (79)
De novo, n (%)379 (53)88 (51)
Estrogen receptor positive and/or progesterone receptor positive, n (%)496 (70)126 (72)
Visceral, n (%)476 (67)108 (62)
≥3 metastatic sites, n (%)232 (33)43 (25)
Liver metastasis, n (%)300 (42)47 (27)
Central nervous system (CNS) metastasis, n (%)45 (6)a15 (9)a
Prior cardiovascular disease, n (%)80 (11)31 (18)
Treatment for early breast cancerb, n (%) Any neoadjuvant or adjuvant therapy Any Hn = 332 293 (88) 187 (56)n = 86 72 (84) 46 (53)
1L treatment patterns, n (%) (Treatments are not mutually exclusive)
With chemotherapy Taxane Docetaxel Paclitaxel Platinum673 (95) 648 (91) 479 (67) 195 (27) 69 (10)117 (67) 87 (50) 34 (20) 51 (29) 40 (23)
With hormonal therapy Aromatase inhibitor Tamoxifen282 (40) 221 (31) 61 (9)94 (54) 76 (44) 14 (8)

 In patients who did not receive H, 25% (16/64) had CNS metastasis.


 In patients with recurrent disease.


Of patients with HER2+ MBC in the real-world SystHERs study, 68% were treated with PH + taxane. Compared with patients who received PH, those who received H without P were older, less commonly had liver metastasis, and more commonly had prior cardiovascular disease, suggesting that these characteristics may have influenced the treatment choice between PH vs H without P.

Clinical trial identification


Legal entity responsible for the study





P.A. Kaufman: Consulting fees from Genentech. Contracted research paid to institution from Genentech/Roche. S.A. Hurvitz: Research funding from Amgen, Bayer, Boehringer Ingelheim, Genentech, GSK, Pfizer, Roche, Biomarin, Merrimack, PUMA, Dignitana, Medication. Research and travel from Lilly, Novartis, OBI Pharma. J. O\'Shaughnessy: Consulting fees from Genentech. G. Mason: Advisory Board: Avon Foundation for Women Scientific. D.A. Yardley: Fees for services from Novartis and Genentech. Contracted research paid to institution from Genentech and Novartis. A. Brufsky: Consulting fees from Roche. H.S. Rugo: Fees for services from Genomic Health. Ccontracted research paid to institution from Genentech, Pfizer, Novartis, Lilly, OBI Pharma, GTX, Macrogenics, Merck. M. Cobleigh: Royalties and Receipt of IP rights from Genomic Health. Consulting fees from Genentech/Roche and GSK. Contracted research from Genentech/Roche, Merrimack, Macrogenics, NRG foundation. S.M. Swain: Consulting fees from Genentech/Roche, Novartis, and Pieris. Contracted research paid to institution from Genentech/Roche, Pfizer, Merrimack, and Lilly. D. Tripathy: Consulting fees from Puma Biotech, NEKTAR Pharma, Novartis. Contracted research paid to institution from Novartis. L. Chu, V. Antao, B. Yoo: Employment at Genentech. Stock ownership in Roche. M. Jahanzeb: Consulting fees from Roche. Data and Safety Monitoring Board for Puma.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.